drugset / Trial / NCT01807481
Phase IV Study to Evaluate the Efficacy and Safety of Mircera in PD
NaSingle-groupOpen-labelTreatment
Summary
The primary objective of study is to evaluate the no of patients which maintain the Hb level between 9.0 \~ 12.0 g/dl during the evaluation period
Timeline
- Start
- 2013-03
- Primary completion
- 2015-02
- Completion
- 2015-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | methoxy polyethylene glycol-epoetin beta | Protein / enzyme biologic | — | — |
Indications
No indication recorded.